Future research should focus on validating these results in diverse cohorts, elucidating TGF-β1’s immunomodulatory effects in the tumor microenvironment, and exploring targeted therapies against TGF-β signaling to improve outcomes in advanced bladder cancer. This evidence concerns the gene TGFB1 and urinary bladder carcinoma.